ERH: A Potential Drug Target and Biomarker for Cancer (G2079)

Target Name: ERH

NCBI ID: G2079

Content of Review Report on ERH Target / Biomarker

ERH

Other Name(s): ERH mRNA splicing and mitosis factor | Enhancer of rudimentary homolog | ERH_HUMAN | DROER

ERH: A Potential Drug Target and Biomarker for Cancer

ERH (erythromycin-resistance transporter) is a gene that has been identified as a drug target and a potential biomarker for various diseases, including cancer. Its function in the body is to transport the drug erythromycin across cell membranes, which is an antibiotic that is commonly used to treat bacterial and fungal infections.

ERH is a transmembrane protein that is expressed in many different tissues and cells in the body. It is primarily localized to the endoplasmic reticulum (ER), which is the part of the cell that synthesizes and stores proteins. ERH is responsible for driving the transport of erythromycin across the ER membrane and into the cytoplasm, where it can interact with and inhibit the activity of various cellular processes, including cell division and protein synthesis.

One of the unique features of ERH is its ability to form a stable complex with erythromycin, allowing it to cross the ER membrane and inhibit the activity of multiple cellular processes at once. This interaction between ERH and erythromycin has been identified as a potential drug target, with studies suggesting that targeting ERH may be a way to treat various diseases that are caused by the over-production or dysfunction of cellular processes that are dependent on erythromycin.

In addition to its potential as a drug target, ERH has also been identified as a potential biomarker for several diseases, including cancer. Its expression has been shown to be elevated in a variety of cancer tissues, and some studies have suggested that targeting ERH may be a way to selectively target and treat specific types of cancer.

One of the challenges in studying ERH as a potential drug target is its complex structure and the fact that it is expressed in many different tissues and cells in the body. However, research into its function and potential as a drug target is ongoing, and there is a growing interest in developing compounds that can specifically interact with ERH and inhibit its activity.

In conclusion, ERH is a transmembrane protein that is expressed in many different tissues and cells in the body. Its function is to transport erythromycin across the ER membrane and into the cytoplasm, where it can interact with and inhibit the activity of various cellular processes. Its interaction with erythromycin has been identified as a potential drug target, and its expression has also been shown to be elevated in a variety of cancer tissues. Further research is needed to fully understand its function and potential as a drug target and biomarker for various diseases.

Protein Name: ERH MRNA Splicing And Mitosis Factor

Functions: May have a role in the cell cycle

The "ERH Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ERH comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets